Abstract
Apixaban is a new oral selective factor Xa inhibitor. Its efficacy and safety are being investigated in a large clinical development program across various indications in venous and arterial thrombotic disorders. A twice-daily regimen was chosen for all the studied indications of apixaban. All three Phase III studies in the prevention of venous thromboembolism after total hip or knee replacement (ADVANCE-1, -2 and -3) have been completed. On the basis of the data obtained so far, apixaban appears to be a promising new drug for the management of thrombotic diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
